01 Cell-Based Immunotherapies Are Expanding Into Solid Tumors The cancer biologics market trends show that cell-based immunotherapies are expanding beyond blood cancers into solid-tumor treatment. This transition is supported by the FDA’s 2024 approval of lifileucel, the first tumor-derived autologous T-cell therapy approved for unresectable or metastatic melanoma, with an objective response rate of 31.5% among 73 patients treated at the recommended dose. The result is a broader role for personalized cellular therapies in solid-tumor oncology and greater development of patient-specific treatment approaches.
02 Antibody-Drug Conjugates Are Expanding Targeted Cancer Treatment The cancer biologics market trends show that antibody-drug conjugates are expanding targeted cancer treatment by combining tumor-directed antibodies with potent therapeutic payloads. This transition is illustrated by the FDA’s May 2026 approval of pivekimab sunirine, a CD123-directed antibody and alkylating-agent conjugate, with 23 of 33 treatment-naïve patients (69.7%) achieving complete or clinical complete remission in the supporting trial. The result is broader use of antibody-based delivery platforms designed to concentrate therapeutic activity on specific cancer cells.
01 Rising Cancer Incidence and Expansion of Biomanufacturing Capacity Drive Market The global cancer burden is creating a large and sustained patient base for biologic therapies, including monoclonal antibodies and other targeted medicines. IARC estimates that 20.6 million people were diagnosed with cancer in 2024, with the annual number projected to reach 34.4 million by 2050, a 67% increase. This expanding treatment population supports demand for biologics used across cancers such as breast, lung, colorectal, and hematological malignancies. The broader patient pool therefore encourages pharmaceutical companies to expand oncology biologic development and commercial supply.Biomanufacturing capacity is strengthening the supply of oncology biologics by providing additional facilities and production capabilities for complex biological medicines. The FDA selected seven companies in June 2026 for its PreCheck pilot program to support new U.S. pharmaceutical manufacturing facilities and increase domestic production capacity. New and expanded facilities can support products such as monoclonal antibodies through larger-scale cell-culture and purification operations, improving manufacturing availability. This additional production capacity supports the growing oncology pipeline and strengthens the supply base for cancer biologics.
01 High Development and Manufacturing Costs and Shorter Product Stability Restrain Cancer Biologics Market Expansion High development and manufacturing costs for cancer biologics arise from complex research, specialized production facilities, controlled processing, and stringent quality requirements. These costs increase treatment prices and can limit affordability, healthcare-provider adoption, and broader patient access.Shorter product stability increases the need for controlled storage, temperature monitoring, and efficient distribution throughout the biologics supply chain. Higher handling requirements can increase logistics costs and product wastage, particularly in regions with limited cold-chain infrastructure, restricting wider market adoption.
01 Bispecific Antibody Therapies and Personalized Cancer Vaccines Create New Market Opportunities Biopharmaceutical companies, antibody developers, and oncology-focused biotechnology firms can expand their portfolios through bispecific antibodies that connect immune cells with cancer targets. Regeneron’s linvoseltamab received FDA approval in July 2025 for relapsed or refractory multiple myeloma, creating revenue avenues through proprietary antibody platforms, licensing, co-development, and specialized oncology therapies.Biotechnology companies, vaccine developers, and genomic technology providers can develop personalized cancer vaccines based on tumor-specific neoantigens. The FDA identifies neoantigen-based personalized vaccines as an active oncology development area, creating opportunities for vaccine platforms, genomic analysis, manufacturing partnerships, and technology licensing.
01 Supply Chain Vulnerabilities and Limited Patient Access to Specialized Cancer Care Hinder Cancer Biologics Market Growth Supply-chain vulnerabilities can disrupt the availability of cancer biologics when manufacturers, distributors, or healthcare systems face shortages or uneven product distribution. In September 2026, WHO identified specific childhood cancer medicines with documented supply gaps, including pegaspargase, asparaginase, dactinomycin, vincristine, and cytarabine, highlighting how supply limitations can restrict treatment availability.Limited access to specialized cancer care restricts the use of biologics that require specialist diagnosis, treatment selection, administration, and monitoring. WHO reported in 2025 that cancer-treatment capacity varies widely between and within countries, while shortages of trained healthcare workers and limited treatment infrastructure continue to constrain access, particularly in lower-resource settings.
June 2026 Roche entered a strategic collaboration with Zealand Pharma to develop and commercialize novel biologic therapies for oncology, strengthening its cancer biologics pipeline with next-generation antibody-based treatments.
May 2026 AstraZeneca completed the acquisition of EsoBiotec, expanding its oncology biologics portfolio with in vivo cell therapy technologies designed to enhance cancer treatment.
October 2025 Bristol Myers Squibb expanded the clinical development program for Opdivo® in combination with novel biologic therapies across multiple solid tumors, aiming to improve treatment outcomes.
June 2025 Merck entered a licensing agreement with Jiangsu Hengrui Pharmaceuticals for an investigational antibody-drug conjugate (ADC), strengthening its oncology biologics pipeline.